The HARMONY consortium

HARMONY is a European Network of Excellence that captures, integrates, analyzes and harmonizes big data from high-quality multidisciplinary sources with the purpose of unlocking valuable knowledge on various hematologic malignancies (HMs).

51 partners

- 44 participants (10 European countries)
- 7 pharmaceutical companies (EFPIA)

HM disease areas with a high unmet need in adult and pediatric patients

- MM multiple myeloma
- AML acute myeloid leukemia
- ALL acute lymphoblastic leukemia
- CLL chronic lymphocytic leukemia
- NHL Non-Hodgkin lymphoma
- MDS myelodysplastic syndrome

The HARMONY consortium big data platform

The HM-specific big data platform developed by HARMONY will enable the more rapid definition of promising treatment strategies, and prediction of adverse events likely to be associated with such strategies.

?? To enhance applicability of the HARMONY platform as a tool to provide guidance on treatment pathways at patient population level

?? To improve reliability and therefore the value of the data

HARMONY shall be taken into account the various demographic features within the EU

The HARMONY consortium stakeholders

The project brings together key stakeholders in the clinical, academic, patient, HTA (health technology assessment), regulatory, economical, ethical and pharmaceutical fields to:

1. rapidly capture the current status in treating HMs
2. define the areas of utmost need for improved patient management
3. redefine the treatment goals based in individualized risk assessments and outcome measures
4. achieve a deeper characterization of HMs in order to improve treatment strategies
5. identify novel treatment targets and drugs
6. foster the design, management, and coordination of innovative clinical and pre-clinical studies
7. generate evidence for cost-effectiveness by pursuing precision medicine approaches
8. provide novel resources and algorithms to more rapidly advance innovative concepts of health care and patient management in the field of HMs